Published in J Virol on December 07, 2011
Crystal structure of glycoprotein C from Rift Valley fever virus. Proc Natl Acad Sci U S A (2013) 1.15
Flaviviruses: braking the entering. Curr Opin Virol (2013) 1.02
Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol (2014) 1.02
Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J Virol (2014) 1.00
Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia. J Virol (2014) 0.98
Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci U S A (2013) 0.97
Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine. PLoS Negl Trop Dis (2012) 0.95
Structural, antigenic, and evolutionary characterizations of the envelope protein of newly emerging Duck Tembusu Virus. PLoS One (2013) 0.92
Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing. MBio (2015) 0.92
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. Virology (2015) 0.91
Crystal structure of the cowpox virus-encoded NKG2D ligand OMCP. J Virol (2012) 0.89
Structure of the St. Louis encephalitis virus postfusion envelope trimer. J Virol (2012) 0.88
Illustrating and homology modeling the proteins of the Zika virus. F1000Res (2016) 0.86
A molecularly cloned, live-attenuated japanese encephalitis vaccine SA14-14-2 virus: a conserved single amino acid in the ij Hairpin of the Viral E glycoprotein determines neurovirulence in mice. PLoS Pathog (2014) 0.84
Relating structure to evolution in class II viral membrane fusion proteins. Curr Opin Virol (2014) 0.83
A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog Mol Biol Transl Sci (2014) 0.83
Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4. Vaccine (2014) 0.82
Envelope protein gene based molecular characterization of Japanese encephalitis virus clinical isolates from West Bengal, India: a comparative approach with respect to SA14-14-2 live attenuated vaccine strain. BMC Infect Dis (2013) 0.80
Structural differences observed in arboviruses of the alphavirus and flavivirus genera. Adv Virol (2014) 0.80
A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. PLoS Pathog (2017) 0.79
The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol Mol Biol Rev (2017) 0.78
Aluminum hydroxide influences not only the extent but also the fine specificity and functional activity of antibody responses to tick-borne encephalitis virus in mice. J Virol (2013) 0.78
Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III. PLoS Negl Trop Dis (2015) 0.78
B cell response and mechanisms of antibody protection to West Nile virus. Viruses (2014) 0.78
Cross-inhibition of chikungunya virus fusion and infection by alphavirus E1 domain III proteins. J Virol (2013) 0.77
The Density Code for the Development of a Vaccine? J Pharm Sci (2016) 0.77
Structure-based mutational analysis of several sites in the E protein: implications for understanding the entry mechanism of Japanese encephalitis virus. J Virol (2015) 0.77
Insight into SNPs and epitopes of E protein of newly emerged genotype-I isolates of JEV from Midnapur, West Bengal, India. BMC Immunol (2017) 0.75
Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus. Sci Rep (2016) 0.75
The Molecular Epidemiology and Evolution of Murray Valley Encephalitis Virus: Recent Emergence of Distinct Sub-lineages of the Dominant Genotype 1. PLoS Negl Trop Dis (2015) 0.75
Conformational changes in intact dengue virus reveal serotype-specific expansion. Nat Commun (2017) 0.75
Epitope Identification and Application for Diagnosis of Duck Tembusu Virus Infections in Ducks. Viruses (2016) 0.75
GRP78 is an important host-factor for Japanese encephalitis virus entry and replication in mammalian cells. J Virol (2017) 0.75
Antibody Responses to Zika Virus Infections in Environments of Flavivirus Endemicity. Clin Vaccine Immunol (2017) 0.75
A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res (2016) 0.75
Near-atomic structure of Japanese encephalitis virus reveals critical determinants of virulence and stability. Nat Commun (2017) 0.75
Identification of a New Broadly Cross-reactive Epitope within Domain III of the Duck Tembusu Virus E Protein. Sci Rep (2016) 0.75
Rab5 and Rab11 are required for clathrin-dependent endocytosis of Japanese encephalitis virus in BHK-21 cells. J Virol (2017) 0.75
mosGCTL-7, a C-Type Lectin Protein, Mediates Japanese Encephalitis Virus Infection in Mosquitoes. J Virol (2017) 0.75
Structural Basis for CD4+ T Cell Epitope Dominance in Arbo-Flavivirus Envelope Proteins: A Meta-Analysis. Viral Immunol (2017) 0.75
Viruses and miRNAs: More Friends than Foes. Front Microbiol (2017) 0.75
Pathogenesis and Inhibition of Flaviviruses from a Carbohydrate Perspective. Pharmaceuticals (Basel) (2017) 0.75
Heat shock protein 90β in the Vero cell membrane binds Japanese encephalitis virus. Int J Mol Med (2017) 0.75
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
Inference of macromolecular assemblies from crystalline state. J Mol Biol (2007) 44.95
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr (2006) 14.21
The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 12.25
The Uppsala Electron-Density Server. Acta Crystallogr D Biol Crystallogr (2004) 9.60
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Structure of the dengue virus envelope protein after membrane fusion. Nature (2004) 7.97
A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A (2003) 7.76
Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme. Proteins (1998) 5.91
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J (2004) 4.05
Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 3.86
Proteolytic activation of tick-borne encephalitis virus by furin. J Virol (1997) 3.78
Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J Virol (1995) 3.67
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol (2005) 3.58
Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol (2001) 3.58
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
Structure of West Nile virus. Science (2003) 3.48
Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep (2003) 3.29
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol (2006) 2.79
Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol (2004) 2.64
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol (2006) 2.33
Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol (2006) 2.20
Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol (2002) 2.18
The flaviviruses (group B arboviruses): a cross-neutralization study. J Gen Virol (1974) 2.18
Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein. J Biol Chem (2003) 2.09
Immature dengue virus: a veiled pathogen? PLoS Pathog (2010) 2.04
N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J Virol (2005) 2.00
Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry. J Biol Chem (1998) 1.94
Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virol (2003) 1.90
Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J (2009) 1.85
Identification of specific histidines as pH sensors in flavivirus membrane fusion. J Cell Biol (2008) 1.83
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
Characterization of neutralizing antibodies to West Nile virus. Virology (2005) 1.81
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol (2009) 1.65
Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol (1995) 1.58
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A (2010) 1.57
Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells. J Biol Chem (2004) 1.56
Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J Virol (2009) 1.52
A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog (2009) 1.41
Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol (2010) 1.41
Cyclic outbreaks of Japanese encephalitis among pigs and humans. Am J Epidemiol (1966) 1.30
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol (2008) 1.26
The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). J Biol Chem (2006) 1.25
Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin. J Biol Chem (2005) 1.23
Protonation of individual histidine residues is not required for the pH-dependent entry of west nile virus: evaluation of the "histidine switch" hypothesis. J Virol (2009) 1.06
Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol (2009) 1.05
Adverse reactions to Japanese encephalitis vaccine in travellers. J Infect (1996) 1.01
The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion. Virology (2009) 1.01
Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E. J Virol (2009) 0.94
Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev (2007) 0.92
Locus of a virus neutralization epitope on the Japanese encephalitis virus envelope protein determined by use of long PCR-based region-specific random mutagenesis. Virology (2001) 0.89
Neurological complications to vaccination against Japanese encephalitis. Eur J Neurol (1998) 0.88
Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine (2000) 0.86
Monoclonal antibodies that disrupt poliovirus only at fever temperatures. J Virol (1993) 0.83
Studies on the antigenic structure of Japanese encephalitis virus using monoclonal antibodies. Microbiol Immunol (1985) 0.82
Capsid destabilization is required for antibody-mediated disruption of poliovirus. J Gen Virol (1994) 0.80
Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A (2002) 5.17
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol (2002) 2.26
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe (2008) 2.16
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol (2003) 2.09
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol (2006) 1.92
Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol (2006) 1.91
Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol (2007) 1.89
Accessory protein recruitment motifs in clathrin-mediated endocytosis. Structure (2002) 1.89
Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J (2009) 1.85
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution. Proc Natl Acad Sci U S A (2009) 1.81
Evidence for MR1 antigen presentation to mucosal-associated invariant T cells. J Biol Chem (2005) 1.72
MR1 uses an endocytic pathway to activate mucosal-associated invariant T cells. J Exp Med (2008) 1.67
The structural immunology of antibody protection against West Nile virus. Immunol Rev (2008) 1.63
Oncogenic potential of the DNA replication licensing protein CDT1. Oncogene (2002) 1.62
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood (2007) 1.55
N-domain-dependent nonphosphorylated STAT4 dimers required for cytokine-driven activation. Nat Immunol (2004) 1.51
Structural mechanism of ER retrieval of MHC class I by cowpox. PLoS Biol (2012) 1.49
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol (2011) 1.49
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog (2013) 1.47
Endogenous MHC-related protein 1 is transiently expressed on the plasma membrane in a conformation that activates mucosal-associated invariant T cells. J Immunol (2011) 1.47
Evidence for a genetic and physical interaction between nonstructural proteins NS1 and NS4B that modulates replication of West Nile virus. J Virol (2012) 1.43
Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol (2005) 1.42
A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog (2009) 1.41
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe (2007) 1.37
Dual engagement regulation of protein interactions with the AP-2 adaptor alpha appendage. J Biol Chem (2004) 1.34
Patterns of nonclassical MHC antigen presentation. Nat Immunol (2007) 1.32
Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol (2007) 1.32
Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog (2012) 1.31
Structural basis of chemokine sequestration by a herpesvirus decoy receptor. Cell (2002) 1.29
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe (2009) 1.27
Biochemical features of the MHC-related protein 1 consistent with an immunological function. J Immunol (2003) 1.27
Structural definition of the F-actin-binding THATCH domain from HIP1R. Nat Struct Mol Biol (2006) 1.26
Capturing a flavivirus pre-fusion intermediate. PLoS Pathog (2009) 1.24
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Structure and intracellular targeting of the SARS-coronavirus Orf7a accessory protein. Structure (2005) 1.16
Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J Biol Chem (2010) 1.13
Ligands for murine NKG2D display heterogeneous binding behavior. Eur J Immunol (2002) 1.12
The role of mhc polymorphism in anti-microbial resistance. Microbes Infect (2004) 1.07
Structural determinants of herpesvirus entry mediator recognition by murine B and T lymphocyte attenuator. J Immunol (2008) 1.06
RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure (2012) 1.04
A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure (2009) 1.03
Disulfide bond engineering to trap peptides in the MHC class I binding groove. J Immunol (2007) 1.02
Structural definition of the H-2Kd peptide-binding motif. J Biol Chem (2006) 1.01
The chemokine binding protein M3 prevents diabetes induced by multiple low doses of streptozotocin. J Immunol (2007) 1.01
The unusual dynamics of parasite actin result from isodesmic polymerization. Nat Commun (2013) 1.01
T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope. J Virol (2009) 1.00
Structural engineering of pMHC reagents for T cell vaccines and diagnostics. Chem Biol (2007) 0.99
Enhanced immune presentation of a single-chain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptide. J Biol Chem (2003) 0.99
Subversion of cytokine networks by virally encoded decoy receptors. Immunol Rev (2012) 0.98
Structural basis of Flavivirus NS1 assembly and antibody recognition. Proc Natl Acad Sci U S A (2014) 0.97
Structural determinants of chemokine binding by an Ectromelia virus-encoded decoy receptor. J Virol (2006) 0.96
A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition. J Virol (2010) 0.96
Recognition of open conformers of classical MHC by chaperones and monoclonal antibodies. Immunol Rev (2005) 0.95
Identification and sequencing of a novel rodent gammaherpesvirus that establishes acute and latent infection in laboratory mice. J Virol (2011) 0.95
Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming. Proc Natl Acad Sci U S A (2012) 0.93
Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology (2011) 0.92
Dual GPCR and GAG mimicry by the M3 chemokine decoy receptor. J Exp Med (2007) 0.92
BTLA and HVEM cross talk regulates inhibition and costimulation. Adv Immunol (2006) 0.91
An unusual Fc receptor-related protein expressed in human centroblasts. Proc Natl Acad Sci U S A (2002) 0.90
Crystal structure of the cowpox virus-encoded NKG2D ligand OMCP. J Virol (2012) 0.89
Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin. J Immunol (2010) 0.89
Structure of the St. Louis encephalitis virus postfusion envelope trimer. J Virol (2012) 0.88
Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides. J Biol Chem (2008) 0.87
The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states. J Virol (2013) 0.86
Natural killer cell-mediated lysis of dorsal root ganglia neurons via RAE1/NKG2D interactions. Eur J Immunol (2003) 0.86
Preparation of stable single-chain trimers engineered with peptide, beta2 microglobulin, and MHC heavy chain. Curr Protoc Immunol (2009) 0.84
Basic and translational applications of engineered MHC class I proteins. Trends Immunol (2010) 0.84
Structural basis for the restoration of TCR recognition of an MHC allelic variant by peptide secondary anchor substitution. J Exp Med (2004) 0.83
Cowpox virus employs a two-pronged strategy to outflank MHCI antigen presentation. Mol Immunol (2013) 0.82
Human C-type lectin domain family 4, member C (CLEC4C/BDCA-2/CD303) is a receptor for asialo-galactosyl-oligosaccharides. J Biol Chem (2011) 0.82
Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody. Virology (2012) 0.81
Structure, expression, and intracellular localization of the SARS-CoV accessory proteins 7a and 7b. Adv Exp Med Biol (2006) 0.81
MMTV superantigens coerce an unconventional topology between the TCR and MHC class II. J Immunol (2014) 0.79
The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1. Virology (2013) 0.78
Oxidative refolding from inclusion bodies. Methods Mol Biol (2014) 0.76
Rodent herpesvirus Peru encodes a secreted chemokine decoy receptor. J Virol (2013) 0.75
Ebola images emerge from the cave. Cell Host Microbe (2008) 0.75
Eukaryotic expression systems for structural studies. Methods Mol Biol (2014) 0.75